Drugs associated with drug-induced interstitial lung diseases

Interstitial lesion is one of the causes of respiratory failure. Drugs are a modifiable etiological factor of lung damage. Medications most commonly associated with drug-induced interstitial lung disease include antineoplastic drugs, disease-modifying anti-rheumatic drugs and amiodarone. According to the latest literature data, the previously described link between anti-rheumatic drugs and interstitial lung diseases is very inconsistent. It may even be a protective effect of this group of drugs on the lung tissue. The relationship between statin use and interstitial lesions is also complex and not fully understood. It is necessary to carefully assess the appearance of respiratory tract complaints in patients taking statins as in other groups of patients. Prescription of additional diagnostic methods is necessary to close monitoring and prevention the toxic effect of these drugs. These actions, as well as the potential prescription of steroid therapy and change in the underlying disease treatment approaches, are an important factor in reducing the incidence of respiratory failure in the population.

1. Macdonald G. Harrison’s Internal Medicine, 17th edition. — by Fauci AS, Kasper DL, Longo DL, et al. Intern Med J. 2008;38(12):932-932. doi: 10.1111/j.1445-5994.2008.01837.x.

2. Skeoch S, Weatherley N, Swift AJ, et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018;7(10):356. doi: 10.3390/jcm7100356.

3. Roelandt M, Demedts M, Callebaut W, et al. Epidemiology of interstitial lung disease (ILD) in flanders: Registration by pneumologists in 1992—1994. Working group on ILD, VRGT. Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding. Acta Clinica Belgica. 1995;50(5):260-8. doi: 10.1080/17843286.1995.11718459.

4. Deidda A, Pisanu C, Micheletto L, et al. Interstitial lung disease induced by fluoxetine: Systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database. Pharmacol Res. 2017;120:294-301. doi:10.1016/j.phrs.2017.04.010.

5. Открытая база данных: Camus P. The Drug-Induced Respiratory Disease Website. [Internet]. [cited 2021 May 5]. Available from: https://www.pneumotox.com/drug/index/

6. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Блеомицин [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_254.htm

7. Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; 1399 рр: 431-449.

8. Blum RH, Carter SK, Agre K. A clinical review of bleomycina new antineoplastic agent. Cancer. 1973;31(4):903-14. doi: 10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n.

9. Delanoy N, Pécuchet N, Fabre E, et al. Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors: A Systematic Review and Meta-analysis. Int J Gynecol Cancer. 2015;25(9):1593-8. doi: 10.1097/IGC.0000000000000530.

10. Roden AC, Camus P. Iatrogenic pulmonary lesions. Semin Diagn Pathol. 2018;35(4):260-271. doi: 10.1053/j.semdp.2018.03.002.

11. O’Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91-6. doi: 10.1093/annonc/mdg020.

12. www.pulmonologyadvisor.com [Internet]. Mark N, Coruh B. Chemotherapy-Related Drug-Induced Lung Injury. [cited 2021 May 5].

13. Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer. 1998;78(8):1061-6. doi:10.1038/bjc.1998.628.

14. Stemmer SM, Cagnoni PJ, Shpall EJ, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol. 1996;14(5):1463-72. doi: 10.1200/JCO.1996.14.5.1463.

15. Reinert T, Baldotto CS, Nunes FA, Scheliga AA. Bleomycin-induced lung injury. J Cancer Res. 2013;480608:9. doi: 10.1155/2013/480608.

16. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179-84. doi: 10.1111/bjh.13419.

17. Distefano G, Fanzone L, Palermo M, et al. HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review. Diagnostics (Basel). 2020;10(4):244. doi: 10.3390/diagnostics10040244.

18. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374(25):2419-29. doi: 10.1056/NEJMoa1510093.

19. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Гемцитабин [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_2071.htm

20. Sahin IH, Geyer AI, Kelly DW, O’Reilly EM. Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications. Clin Colorectal Cancer. 2016;15(1):24-31. doi: 10.1016/j.clcc.2015.08.003.

21. Yang ZY, Yuan JQ, Di MY, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8(3):e57528. doi: 10.1371/journal.pone.0057528.

22. Wang Y, Hu GF, Zhang QQ, et al. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1961-72. doi: 10.2147/DDDT.S105442.

23. Tamura M, Saraya T, Fujiwara M, et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist. 2013;18(4):454-9. doi: 10.1634/theoncologist.2012-0248.

24. Hamada T, Yasunaga H, Nakai Y, et al. Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study. Respirology. 2016;21(2):338-43. doi: 10.1111/resp.12665.

25. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008;133(2):528-38. doi: 10.1378/chest.07-0851.

26. Osawa M, Kudoh S, Sakai F, et al. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol. 2015;20(6):1063-71. doi: 10.1007/s10147-015-0834-3.

27. Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci. 2014;105(12):1584-90. doi: 10.1111/cas.12550.

28. Sumpter K, Harper-Wynne C, O’Brien M, et al. Severe acute interstitial pneumonia and gefitinib. Lung Cancer 2004;43(3):3678. doi:10.1016/j.lungcan.2003.09.016.

29. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. Lung Cancer. 2014;83(2):231-9. doi: 10.1016/j.lungcan.2013.11.016.

30. Qi WX, Sun YJ, Shen Z, Yao Y. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a metaanalysis of 24 phase III clinical trials. J Chemother. 2015;27(1):40-51. doi: 10.1179/1973947814Y.0000000189.

31. Jain A, Shannon V, Sheshadri A. Pneumonitis after precision oncology therapies: A concise review. J Immunother Precis Oncol. 2018;1(1):26-37. doi:10.4103/JIPO.JIPO_9_18.

32. Peerzada MM, Spiro TP, Daw HA. Pulmonary toxicities of tyrosine kinase inhibitors. Clin Adv Hematol Oncol. 2011;9(11):824-36.

33. Kudoh S, Kato H, Nishiwaki Y, et al.; Japan Thoracic Radiology Group. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008;177(12):1348-57. doi: 10.1164/rccm.200710-1501OC.

34. Boku N, Sugihara K, Kitagawa Y, et al. Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients. Jpn J Clin Oncol. 2014;44(3):214-23. doi: 10.1093/jjco/hyt196.

35. Masahiro E, Johkoh T, Kimura K, Nobuyuki Y. Imaging of gefitinibrelated interstitial lung disease: Multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung cancer.2006;52(2):135-40. doi:10.1016/j.lungcan.2006.02.002.

36. Ctep.cancer.gov [Internet]. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). [cited 2021 May 5]. Available from https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf

37. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Сиролимус [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_3079.htm

38. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Эверолимус [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_3522.htm

39. White DA, Camus P, Endo M, et al. Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. Am J Respir Crit Care Med. 2010;182(3):396-403. doi: 10.1164/rccm.200911-1720OC.

40. Iacovelli R, Palazzo A, Mezi S, et al. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol. 2012;51(7):873-9. doi: 10.3109/0284186X.2012.705019.

41. Maroto JP, Hudes G, Dutcher JP, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol. 2011;29(13):1750-6. doi: 10.1200/JCO.2010.29.2235.

42. Nishino M, Boswell EN, Hatabu H, et al. Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. Oncologist. 2015;20(9):1077-83. doi: 10.1634/theoncologist.2015-0033.

43. Weiner SM, Sellin L, Vonend O, et al. Pneumonitis associated with sirolimus: Clinical characteristics, risk factors and outcome—A single-centre experience and review of the literature. Nephrol Dial Transplant. 2007;22(12):3631-7. doi: 10.1093/ndt/gfm420.

44. Yonemori K, Hirakawa A, Kawachi A, et al. Drug induced interstitial lung disease in oncology phase I trials. Cancer Sci. 2016;107(12):1830-1836. doi: 10.1111/cas.13087.

45. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006;42(12):1875-80. doi: 10.1016/j.ejca.2006.03.015.

46. Albiges L, Chamming’s F, Duclos B, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol. 2012;23(8):1943-1953. doi: 10.1093/annonc/mds115.

47. Willemsen AE, Grutters JC, Gerritsen WR, et al. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. Int J Cancer. 2016;138(10):2312-21. doi: 10.1002/ijc.29887.

48. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Ниволумаб [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_6773.htm

49. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Авелумаб [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_7047.htm

50. Okada N, Matsuoka R, Sakurada T, et al. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Sci Rep. 2020;10(1):13773. doi:10.1038/s41598-020-70743-2.

51. Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest. 2017;152(2):271-281. doi: 10.1016/j.chest.2017.04.177.

52. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709-717. doi: 10.1200/JCO.2016.68.2005.

53. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377(14):1345-1356. doi: 10.1056/NEJMoa1709684.

54. Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050. doi: 10.1183/13993003.00050-2017.

55. Nishino M, Ramaiya NH, Awad MM, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016;22(24):6051-6060. doi: 10.1158/1078-0432.CCR-16-1320.

56. Nishino M, Sholl LM, Hodi FS, et al. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015;373(3):288-90. doi: 10.1056/NEJMc1505197.

57. Nishino M, Chambers ES, Chong CR, et al. Anti-PD-1 InhibitorRelated Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2016;4(4):289-93. doi: 10.1158/2326-6066.CIR-15-0267.

58. Nishino M, Hatabu H, Hodi FS, Ramaiya NH. Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. JCO Precis Oncol. 2017;1:PO.17.00026. doi: 10.1200/PO.17.00026.

59. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol. 2016;2(10):1346-1353. doi: 10.1001/jamaoncol.2016.1051.

60. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Кармустин [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_1929.htm

61. Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant. 2000;25(3):309-13. doi: 10.1038/sj.bmt.1702154.

62. Schmitz N, Diehl V. Carmustine and the lungs. Lancet. 1997;349(9067):1712-3. doi: 10.1016/s0140-6736(05)62951-0.

63. Aronin PA, Mahaley MS Jr, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med. 1980;303(4):183-8. doi: 10.1056/NEJM198007243030403.

64. O’Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990;323(6):378-82. doi: 10.1056/NEJM199008093230604.

65. Phillips GL, Fay JW, Herzig GP, et al. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) autologous bone marrow transplantation therapy of refractory cancer: a preliminary report. Exp Hematol. 1979;7 Suppl 5:372-83.

66. Durant JR, Norgard MJ, Murad TM, et al. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med. 1979;90(2):191-4. doi: 10.7326/0003-4819-90-2-191.

67. Wilczynski SW, Erasmus JJ, Petros WP, et al. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med. 1998;157(2):565-73. doi: 10.1164/ajrccm.157.2.9705072.

68. Chap L, Shpiner R, Levine M, et al. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplant. 1997;20(12):1063-7. doi: 10.1038/sj.bmt.1701028.

69. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Ритуксимаб [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_2695.htm

70. Lioté H, Lioté F, Séroussi B, et al. Rituximab-induced lung disease: A systematic literature review. Eur Respir J. 2010;35(3):681-7. doi: 10.1183/09031936.00080209.

71. Hadjinicolaou AV, Nisar MK, Bhagat S, et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. Rheumatology (Oxford). 2011;50(12):2297-305. doi: 10.1093/rheumatology/ker289.

72. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol. 2007;82(10):916-9. doi: 10.1002/ajh.20910.

73. Zayen A, Rais H, Rifi H, et al. Rituximab-induced interstitial lung disease: case report and literature review. Pharmacology. 2011;87(5-6):318-20. doi: 10.1159/000327681.

74. rheumatolog.su [интернет]. Клинические рекомендации. Ревматоидный артрит. Минздрав России, Ассоциация ревматологов России. Пересмотр 2018 г. [доступ от 04.05.2021]. Доступ по ссылке https:///media/media/2018/07/18/clinrec_rheumart.pdf

75. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613-26. doi: 10.1016/j.semarthrit.2013.09.005.

76. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Метотрексат [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_955.htm

77. Fragoulis GE, Nikiphorou E, Larsen J, et al. Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment. Front Med (Lausanne). 2019;6:238. doi: 10.3389/fmed.2019.00238.

78. Pavy S, Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73(4):388-95. doi: 10.1016/j.jbspin.2006.01.007.

79. Drosos AA, Psychos D, Andonopoulos AP, et al. Methotrexate therapy in rheumatoid arthritis: A two year prospective follow-up. Clin Rheumatol. 1990;9(3):333-41. doi: 10.1007/BF02114393.

80. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127(5):356-64. doi: 10.7326/0003-4819-127-5-199709010-00003.

81. Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology. 1994;107(1):266-70. doi: 10.1016/0016-5085(94)90085-x.

82. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15(2):373-81. doi: 10.1034/j.1399-3003.2000.15b25.x.

83. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997;40(10):1829-37. doi: 10.1002/art.1780401016.

84. Suwa A, Hirakata M, Satoh S, et al. Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy. Clin Exp Rheumatol. 1999;17(3):355-8.

85. Picchianti Diamanti A, Markovic M, Argento G, et al. Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review. Ther Adv Respir Dis. 2017;11(1):64-72. doi: 10.1177/1753465816668780.

86. Conway R, Low C, Coughlan RJ, et al. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803-12. doi: 10.1002/art.38322.

87. Dawson JK, Quah E, Earnshaw B, et al. Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review. Rheumatol Int. 2021;41(6):1055-1064. doi: 10.1007/s00296-020-04773-4.

88. Ibfelt EH, Jacobsen RK, Kopp TI, et al. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology (Oxford). 2021;60(1):346-352. doi: 10.1093/rheumatology/keaa327.

89. Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021;57(2):2000337. doi: 10.1183/13993003.00337-2020.

90. Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019;9(5):e028466. doi: 10.1136/bmjopen-2018-028466.

91. Rojas-Serrano J, Herrera-Bringas D, Pérez-Román DI, et al. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol. 2017;36(7):1493-1500. doi: 10.1007/s10067-017-3707-5.

92. rlsnet.ru [интернет]. РЛС. Реестр лекарственных средств России. Лефлуномид. [доступ от 05.05.2021]. Доступ по ссылке https://www.rlsnet.ru/mnn_index_id_2819.htm

93. Sawada T, Inokuma S, Sato T, et al. Study Committee for Leflunomideinduced Lung Injury, Japan College of Rheumatology. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(9):1069-72. doi: 10.1093/rheumatology/kep052.

94. Chikura B, Lane S, Dawson JK. Clinical expression of leflunomideinduced pneumonitis. Rheumatology (Oxford). 2009;48(9):1065-8. doi: 10.1093/rheumatology/kep050.

95. Sato T, Inokuma S, Sagawa A, et al; Study Committee for Leflunomideinduced Lung Injury, Japan College of Rheumatology. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(10):1265-8. doi: 10.1093/rheumatology/kep227.

96. Raj R, Nugent K. Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(3):167-76.

97. Conway R, Low C, Coughlan RJ, et al. Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. J Rheumatol. 2016;43(5):855-60. doi: 10.3899/jrheum.150674.

98. Olivas-Flores EM, Bonilla-Lara D, Gamez-Nava JI, et al. Interstitial lung disease in rheumatoid arthritis: Current concepts in pathogenesis, diagnosis and therapeutics. World J Rheumatol. 2015;5(1):1-22. doi: 10.5499/wjr.v5.i1.1.

99. Jani M, Hirani N, Matteson EL, Dixon WG. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol. 2014;10(5):284-94. doi: 10.1038/nrrheum.2013.197.

100. Sen S, Peltz C, Jordan K, Boes TJ. Infliximab-induced nonspecific interstitial pneumonia. Am J Med Sci. 2012;344(1):75-8. doi: 10.1097/MAJ.0b013e31824c07e8.

101. Wiener CM, Muse VV, Mark EJ. Case records of the Massachusetts General Hospital. Case 33-2008. A 63-year-old woman with dyspnea on exertion. N Engl J Med. 2008;359(17):1823-32. doi: 10.1056/NEJMcpc0806979.

102. Taki H, Kawagishi Y, Shinoda K, et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int. 2009;30(2):275-6. doi: 10.1007/s00296-009-0931-6.

103. Kuroki M, Noguchi Y, Shimono M, et al. Repression of bleomycininduced pneumopathy by TNF. J Immunol. 2003;170(1):567-74. doi: 10.4049/jimmunol.170.1.567.

104. Elias JA. Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandindependent and -independent mechanisms. Am Rev Respir Dis. 1988;138(3):652-8. doi: 10.1164/ajrccm/138.3.652.

105. Sullivan DE, Ferris M, Nguyen H, et al. TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J Cell Mol Med. 2009;13(8B):1866-76. doi: 10.1111/j.1582-4934.2009.00647.x.

106. Cassone G, Manfredi A, Vacchi C, et al Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. J Clin Med. 2020;9(4):1082. doi: 10.3390/jcm9041082.

107. scardio.ru [интернет]. Клинические рекомендации. Фибрилляция и трепетание предсердий. Минздрав России, Российское кардиологическое общество при участии: Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции; Ассоциации сердечно-сосудистых хирургов России. Пересмотр 2020 г. [доступ от 04.05.2021]. Доступ по ссылке https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf

108. scardio.ru [интернет]. Клинические рекомендации. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Минздрав России, Российское кардиологическое общество при участии: Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции; Всероссийской общественной организации «Ассоциации детских кардиологов России»; Общества холтеровского мониторирования и неинвазивной электрокардиологии. Пересмотр 2020 г. [доступ от 04.05.2021]. Доступ по ссылке https://scardio.ru/content/Guidelines/2020/Clinic_rekom_ZHNR.pdf

109. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312-22. doi: 10.1001/jama.298.11.1312.

110. Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med. 1984;101(4):462-9. doi: 10.7326/0003-4819-101-4-462.

111. Polkey MI, Wilson PO, Rees PJ. Amiodarone pneumonitis: no safe dose. Respir Med. 1995;89(3):233-5. doi: 10.1016/0954-6111(95)90254-6.

112. Ott MC, Khoor A, Leventhal JP, et al. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest. 2003;123(2):646-51. doi: 10.1378/chest.123.2.646.

113. Camus P, Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Clin Chest Med. 2004;25(1):65-75. doi: 10.1016/S0272-5231(03)00144-8.

114. Jessurun GA, Crijns HJ. Amiodarone pulmonary toxicity. BMJ. 1997;314(7081):619-20. doi: 10.1136/bmj.314.7081.619.

115. Marchlinski FE, Gansler TS, Waxman HL, Josephson ME. Amiodarone pulmonary toxicity. Ann Intern Med. 1982;97(6):839-45. doi: 10.7326/00034819-97-6-839.

116. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16(2):43-8. doi: 10.1155/2009/282540.

117. Okayasu K, Takeda Y, Kojima J, et al. Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse. Intern Med. 2006;45(22):1303-7. doi: 10.2169/internalmedicine.45.1800.

118. Sunderji R, Kanji Z, Gin K. Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance. Can J Cardiol. 2000;16(11):1435-40.

119. Goldschlager N, Epstein AE, Naccarelli GV, et al; Practice Guidelines Sub-committee, North American Society of Pacing and Electrophysiology (HRS). A practical guide for clinicians who treat patients with amiodarone. Heart Rhythm. 2007;4(9):1250-9. doi: 10.1016/j.hrthm.2007.07.020.

120. Lalic K, Trkanjec JT, Šimic M, Tudoric N. Statin-induced lung diseases. Eur Respir J. 2006;48:abstr. PA834. doi: 10.1183/13993003.congress-2016.

121. Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest. 2008;134(4):824-30. doi: 10.1378/chest.08-0943.

122. open.fda.gov [Internet]. FDA Adverse Event Reporting System [cited 2021 May 4]. Available from: https://open.fda.gov/data/faers/

123. Lantuejoul S, Brambilla E, Brambilla C, Devouassoux G. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J. 2002;19(3):577-80. doi: 10.1183/09031936.02.00258802.

124. Lüllmann H, Lüllmann-Rauch R, Wassermann O. Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol. 1975;4(2):185-218. doi: 10.1080/10408447509164014.

125. Seiler KU, Wassermann O. Drug-induced phospholipidosis. II. Alterations in the phospholipid pattern of organs from mice, rats and guineapigs after chronic treatment with chlorphentermine. Naunyn Schmiedebergs Arch Pharmacol. 1975;288(2-3):261-8. doi: 10.1007/BF00500531.

126. Liebhaber MI, Wright RS, Gelberg HJ, et al. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest. 1999;115(3):886-9. doi: 10.1378/chest.115.3.886.

127. Liscoët-Loheac N, André N, Couturaud F, et al. Hypersensitivity pneumonitis in a patient taking pravastatin. Rev Mal Respir. 2001;18(4 Pt 1):426-8.

128. Veyrac G, Cellerin L, Jolliet P. Un cas de pneumopathie interstitielle rapporté sous atorvastatine (Tahor): synthèse des cas publiés sous statins. Therapie. 2006;61(1):57-67. [A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins (in French).] doi: 10.2515/therapie:2006017.

129. Vedel-Krogh S, Nielsen SF, Nordestgaard BG. Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease. PLoS One. 2015;10(10):e0140571. doi: 10.1371/journal.pone.0140571.

130. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61(8):729-34. doi: 10.1136/thx.2005.057976.